Fig. 1From: Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trialsStudy design of the N-of-trial. CBD, cannabidiol; FU, follow-upBack to article page